Drugs / INV-6452
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07612891 | Jul 2025 → Feb 2028 expected | endometrial cancer, female breast carcinoma, ovarian cancer | Shenzhen Ionova Life Sciences Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INV-6452 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07612891 ↗ |
| Route | Oral | “once daily orally” NCT07612891 ↗ |